Circulating anti-Ro/SSA-antibodies and risk of heart rate-corrected QT interval prolongation: a meta-analysis

Clicks: 28
ID: 324995
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Backgrounds Accumulating evidence indicates that anti-Ro/Sjögren’s syndrome-related antigen A(SSA)-antibodies, specifically the anti-Ro/SSA-52kD subtype, can promote heart rate-corrected QT interval(QTc) prolongation by inhibiting the hERG-K+ channel. However, the numerous clinical studies published over the past two decades yielded conflicting results. Objective This meta-analysis aims at pooling the available data to provide clarity on this clinically relevant issue. Methods A systematic review was performed for clinical studies comparing QTc in anti-Ro/SSA-positive vs. -negative subjects. Standardized mean differences(SMDs) and odds ratios(ORs) were compared using random effects models. The risk of bias was assessed using RoBANS2, Egger's test and contour-enhanced funnel plots. Results Twenty-five studies were included, pooling 2,122 anti-Ro/SSA-positive and 8,865 anti-Ro/SSA-negative subjects. Overall, anti-Ro/SSA-positivity is associated with a longer QTc(SMD=0.36[0.18–0.53], p<0.001), and a >2-times higher risk of QTc prolongation(2.24[1.54-3.27], p<0.001). Several sub-analyses supported and refined these findings. Specifically, in anti-Ro/SSA-positive patients with unselected CTD, QTc absolute values are higher(SMD=0.57[0.20-0.94], p=0.002) and QTc prolongation occurs more frequently(OR=7.62[2.50-23.21], p<0.001) than in negative patients; furthermore, QTc prolongation is also more common in SLE patients with circulating anti-Ro/SSA-antibodies than in those without(OR=1.86[1.19–2.90], p=0.006). Finally, in anti-Ro/SSA-52kD-positive subjects, the QTc is longer compared to the negative ones(SMD=0.43[0.15–0.71], p=0.002). Conclusions This meta-analysis supports the conclusion that circulating anti-Ro/SSA-antibodies per se represents a significant risk factor for QTc prolongation. However, the presence of several conflicting studies suggests that a more accurate investigation of specific factors, such as the impact of individual antibody subtype levels(anti-52kD/anti-60kD), will be critical to fully clarify the topic and its implications in clinical practice.
Reference Key
openalex_W7203439864 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pietro Enea Lazzerini, Mark M. Melamud, Evgeny A. Ermakov, Vadim Vyacheslavovich Kon'kov, Valentina N. Buneva, Riccardo Accioli, Alessandra Cartocci, Anna Cantore, Viola Salvini, Decoroso Verrengia, Maurizio Acampa, Pier Leopoldo Capecchi, Mohamed Boutjdir
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag123
URL
https://doi.org/10.1093/ehjopen/oeag123
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.